Expert Review of Neurotherapeutics最新文献_第5页

Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments. 脆性X综合征的行为困难：当前的药理学选择和潜在的未来发展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1080/14737175.2025.2510408

Andrew C Stanfield, Andrew G McKechanie

{"title":"Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments.","authors":"Andrew C Stanfield, Andrew G McKechanie","doi":"10.1080/14737175.2025.2510408","DOIUrl":"10.1080/14737175.2025.2510408","url":null,"abstract":"Introduction: Fragile X Syndrome (FXS) is the most frequent inherited form of intellectual disability and a common cause of autism spectrum disorders and other neurodevelopmental conditions. It is commonly associated with hyperarousal, anxiety, and behavioral difficulties such as agitation, self-injurious behavior, and aggression.Areas covered: This narrative review covers the physical, cognitive, and behavioral phenotype associated with FXS and the evidence for pharmacological interventions for behavioral difficulties, including those prescribed on the basis of symptoms and those aimed at the pathophysiological mechanisms of FXS ('targeted' interventions). Consideration is then given to the evidence for novel targeted treatments currently in later stages of clinical development.Expert opinion: The first-line management of behavioral difficulties are non-pharmacological interventions, and there are only a few studies in FXS to guide pharmacological approaches. Identification and management of anxiety and ADHD, which contribute to behavioral difficulties, are important steps before considering antipsychotic treatment for agitation, aggression, or self-injurious behavior. The evidence for repurposed targeted treatments remains based on small RCTs or open-label studies; therapeutic trials of these interventions therefore need close monitoring. Multiple novel medications are in clinical development; genetic therapies remain preclinical but are likely to be important in the coming years.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"857-867"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Insights and Strategies to Managing Depression Subtypes Associated with Tobacco dependence: A Response to the Letter to the Editor. 管理与烟草依赖相关的抑郁症亚型的临床见解和策略：对致编辑的信的回应。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1080/14737175.2025.2506463

Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio, Giulia Menculini, Valerio Ricci, Mauro Pettorruso, Umberto Volpe, Giovanni Martinotti

引用次数: 0

Multimodal approaches to the treatment of personality disorder. 治疗人格障碍的多模式方法。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-19 DOI: 10.1080/14737175.2025.2515066

Peter Tyrer, Jacob King, Roger Mulder

{"title":"Multimodal approaches to the treatment of personality disorder.","authors":"Peter Tyrer, Jacob King, Roger Mulder","doi":"10.1080/14737175.2025.2515066","DOIUrl":"10.1080/14737175.2025.2515066","url":null,"abstract":"Introduction: Personality disorder is the most common of all psychiatric disorders and is best perceived as a diagnostic spectrum extending from no personality dysfunction to severe personality disorder. The position on the spectrum is determined mainly by problems in interpersonal social dysfunction, self-perception and awareness, and dangers to the self and others.Areas covered: We examine psychological and psychodynamic treatments, pharmacotherapy, neuromodulation and other related approaches, environmental treatments, and therapeutic communities. Although many published studies refer to individual categories, these are now linked to the diagnostic spectrum in this review.Expert opinion: There is some evidence that focused psychological treatments linked to problem solving (STEPPS), mentalization based therapy and dialectical behavior therapy, are successful in treating moderately severe personality disorder, especially regarding self-harm, but there is also benefit from well organized standard care that is similarly effective. There is no good evidence that drug treatment is of real value in personality disorder. Brain stimulation approaches have limited evidence. Psychodynamic approaches, environmental interventions, nidotherapy, and therapeutic communities appear to be of some value, but good data are few. Long-term studies of treatment effectiveness are few but some show that personality disorder can respond to treatment and remit.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"869-879"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing cognitive impairment among pediatric epilepsies: a systematic review. 评估儿童癫痫患者的认知障碍：一项系统综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1080/14737175.2025.2508776

Erika Maria Giannola, Laura Siri, Pasquale Striano, Antonella Riva

{"title":"Assessing cognitive impairment among pediatric epilepsies: a systematic review.","authors":"Erika Maria Giannola, Laura Siri, Pasquale Striano, Antonella Riva","doi":"10.1080/14737175.2025.2508776","DOIUrl":"10.1080/14737175.2025.2508776","url":null,"abstract":"Background: Epilepsy is a chronic neurological disorder that varies both for etiopathology and impact on cognitive, intellectual, and adaptive development in children with epilepsy (CWE). CWE may present with reduced attention, memory as well as learning skills, and impaired executive and emotional-behavioral functioning, which can impact both the patient's and their family's Quality of Life (QoL).Methods: This systematic review investigates the tools and scales used to assess cognition in CWE, following the PRISMA guidelines. PubMed was used as primary source database and studies published between January 2020 and December 2024 were reviewed for inclusion/exclusion criteria.Results: The authors' search yielded 3,398 articles of which 2,486 (73%) papers were excluded based on title and abstract only. Of the 912 remaining records, 844 did not meet the inclusion criteria. Sixty-eight studies met the inclusion criteria. The total number of epilepsy patients (EP) in the included studies was 4,530. The Wechsler intelligence scale for children was the most administered test to evaluate cognitive impairment.Conclusions: The included studies highlighted the relevance of the impaired neuropsychological functioning in CWE, although deep heterogeneity in the assessment still invalidates comparability. Further research is needed to provide comprehensive care of CWE, enhancing cognitive functions and considering the impact of the illness on QoL and mental health.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"753-772"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2024-09-08 DOI: 10.1080/14737175.2024.2398883

引用次数: 0

Could self-reporting sleep duration become an important tool in the prediction of dementia? 自我报告睡眠时间能否成为预测痴呆的重要工具？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-17 DOI: 10.1080/14737175.2025.2506459

Marina Šagud, Maja Bajs Janović, Suzana Uzun, Biljana Kosanović Rajačić, Oliver Kozumplik, Nela Pivac

{"title":"Could self-reporting sleep duration become an important tool in the prediction of dementia?","authors":"Marina Šagud, Maja Bajs Janović, Suzana Uzun, Biljana Kosanović Rajačić, Oliver Kozumplik, Nela Pivac","doi":"10.1080/14737175.2025.2506459","DOIUrl":"10.1080/14737175.2025.2506459","url":null,"abstract":"Introduction: Optimal sleep duration is increasingly recognized as an important determinant of overall health, including cognitive functioning. Studies often report a U- or J-shaped relationship between sleep duration and incident dementia or cognitive deterioration, whereas long sleep, the extremes of sleep duration, and the transition to long sleep were particularly detrimental. In preclinical studies, partial or complete sleep deprivation produced inflammation, oxidative stress, as well as increased tau hyperphosphorylation and amyloid-β burden. In humans, although the findings are less pronounced, they still highlight that transitioning to an excessive sleep duration is associated with neurodegeneration. Moreover, the association between sleep duration and dementia is complex and modified by genetic, psychosocial and lifestyle factors, along with psychiatric and somatic comorbidities.Areas covered: The purpose of this perspective is to summarize the current knowledge on the association between sleep duration and dementia. It is based on a literature search for meta-analyses of prospective studies with sleep duration as an exposure and dementia as an outcome.Expert opinion: Sleep duration is a modifiable risk factor for dementia while long sleep may be an early sign of neurodegeneration. Therefore, self-reported sleep duration is an easy-to-use tool for detecting individuals who may be at risk for cognitive deterioration.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"737-751"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tobacco use disorder and depression: emerging strategies and recommendations. 烟草使用障碍和抑郁症：新出现的战略和建议。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1080/14737175.2025.2506460

Raul Felipe Palma-Alvarez

引用次数: 0

Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms. 多发性硬化症的神经保护策略：现状更新和新兴范例。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-06-03 DOI: 10.1080/14737175.2025.2510405

Catalina I Coclitu, Cris S Constantinescu, Radu Tanasescu

{"title":"Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms.","authors":"Catalina I Coclitu, Cris S Constantinescu, Radu Tanasescu","doi":"10.1080/14737175.2025.2510405","DOIUrl":"10.1080/14737175.2025.2510405","url":null,"abstract":"Introduction: MS is a disease continuum in which maladaptive inflammation and neurodegeneration co-occur from onset and evolve over time. Recent progress in the understating of MS pathobiology creates new perspectives for novel neuroprotective therapeutic strategies.Areas covered: The authors briefly review the mechanisms underlying inflammation and neurodegeneration in MS and discuss the current and emerging strategies to promote neuroprotection in MS. Data were derived in large part from extensive review of the published literature available on PubMed (up to 5th of March 2025).Expert opinion: Strategies for neuroprotection should be ideally implemented early in the course of MS. They should consider the interplay between neuroinflammation, demyelination and neurodegeneration, the maladaptive changes in the CNS innate immunity resident cells, axonal mitochondrial dysfunction (axonal response of mitochondria to demyelination, ARMD), and remyelination. There is a need for adequate biomarkers that can help to monitor outcomes of target engagement. Comorbidities and aging can worsen neurodegeneration and impair neuroprotective/regenerative processes. Candidate drugs from preclinical and early clinical studies should be tested in multi-arm multistage adaptive trials.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"791-817"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: the era of regenerative medicine. 肌萎缩性侧索硬化症治疗和管理的最新进展：再生医学的时代。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-07-01 Epub Date: 2025-05-21 DOI: 10.1080/14737175.2025.2508781

Fabiola De Marchi, Ivan Lombardi, Alessandro Bombaci, Luca Diamanti, Marco Olivero, Elisa Perciballi, Danilo Tornabene, Edvige Vulcano, Daniela Ferrari, Letizia Mazzini

{"title":"Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: the era of regenerative medicine.","authors":"Fabiola De Marchi, Ivan Lombardi, Alessandro Bombaci, Luca Diamanti, Marco Olivero, Elisa Perciballi, Danilo Tornabene, Edvige Vulcano, Daniela Ferrari, Letizia Mazzini","doi":"10.1080/14737175.2025.2508781","DOIUrl":"10.1080/14737175.2025.2508781","url":null,"abstract":"Introduction: Despite decades of research, effective disease-modifying treatments for Amyotrophic Lateral Sclerosis (ALS) remain scarce. The emergence of regenerative medicine presents a new frontier for ALS treatment.Areas covered: This review is based on a comprehensive literature search using PubMed, Scopus and clinical trials databases on the recent therapeutic advancements in ALS, giving focus to regenerative medicine. The article includes coverage of stem cell-based therapies, including mesenchymal, neural and induced pluripotent stem cells; all of which may offer potential neuroprotective and immunomodulatory effects. Gene therapy, particularly antisense oligonucleotides targeting ALS-related mutations, has gained traction, with tofersen becoming the first FDA-approved genetic therapy for ALS. The article also covers emerging approaches such as extracellular vesicles, immune-modulating therapies, and bioengineering techniques, including CRISPR-based gene editing and cellular reprogramming, that hold promise for altering disease progression.Expert opinion: While regenerative medicine provides hope for ALS patients, significant challenges remain. Biomarkers will play a crucial role in guiding personalized treatment strategies, ensuring targeted interventions. Future research should prioritize optimizing combinatory approaches, integrating different therapy strategies to maximize patient outcomes. Although regenerative medicine is still in its early clinical stages, its integration into ALS treatment paradigms could redefine disease management and alter its natural course.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"773-789"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The differential diagnosis of autism spectrum disorder in adults. 成人自闭症谱系障碍的鉴别诊断。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1080/14737175.2025.2490533

Hannah M Carroll, Robyn P Thom, Christopher J McDougle

{"title":"The differential diagnosis of autism spectrum disorder in adults.","authors":"Hannah M Carroll, Robyn P Thom, Christopher J McDougle","doi":"10.1080/14737175.2025.2490533","DOIUrl":"10.1080/14737175.2025.2490533","url":null,"abstract":"Introduction: Diagnosing autism spectrum disorder (ASD) in adults is challenging due to its heterogeneity and symptom overlap with other conditions. Making an accurate diagnosis can be difficult and overwhelming but is vital for proper accommodations and interventions while avoiding unproductive or harmful treatments.Areas covered: The authors have based their review on a comprehensive literature search using PubMed, PsycINFO, and Google Scholar to identify relevant recommendations, diagnostic tools, and common differential diagnoses for adults with ASD. A clinical framework is provided based on the DSM-5 criteria, starting with an evaluation of childhood symptom onset and persistent manifestations of the core criteria - social and communication impairment, along with restricted, repetitive behaviors. Conditions with overlapping presentations, including personality disorders, anxiety, depression, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, and schizophrenia, are discussed, as well as challenges in differentiating these from ASD.Expert opinion: Many factors complicate diagnosing ASD in adults - such as skewed public perception or misinformation spread on social media. Existing tools frequently miss subtle or atypical presentations, particularly in underdiagnosed groups like women and older adults. Promising advances in machine learning and artificial intelligence will hopefully improve diagnostic precision in the future. Up-to-date clinician training and large-scale research remain paramount for refining adult ASD diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"635-648"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0